Periscope Capital’s Apexigen, Inc. Common Stock APGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-270,400
Closed -$2.75M 1171
2022
Q2
$2.75M Sell
270,400
-146,300
-35% -$1.48M 0.07% 494
2022
Q1
$4.2M Sell
416,700
-300
-0.1% -$3.01K 0.11% 381
2021
Q4
$4.17M Sell
417,000
-200
-0% -$1.99K 0.11% 351
2021
Q3
$4.15M Sell
417,200
-200
-0% -$1.98K 0.12% 319
2021
Q2
$4.14M Hold
417,400
0.14% 308
2021
Q1
$4.1M Buy
+417,400
New +$4.17M 0.16% 251

Other funds holding APGN

Periscope Capital's APGN Position: Q3 2022 in Review

Periscope Capital sold out of Apexigen, Inc. Common Stock (APGN) in Q3 2022, closing a stake of 270,400 shares — an estimated $2.75M sold.

Periscope Capital first reported a position in APGN in Q1 2021 and held it in 6 quarters. The position peaked at $4.2M in Q1 2022. 18 funds tracked by Wall St. Rank hold APGN as of Q3 2022.

  • Periscope Capital reported no remaining Apexigen, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Periscope Capital sold 270,400 Apexigen, Inc. Common Stock shares in Q3 2022, an estimated $2.75M.
  • Periscope Capital first reported a position in Apexigen, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
  • Periscope Capital's Apexigen, Inc. Common Stock position peaked at $4.2M in Q1 2022.
  • 18 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q3 2022.

Based on Periscope Capital's 13F filing for Q3 2022, filed 8 Nov 2022.